Patients with stable angina pectoris who undergo percutaneous coronary intervention
Conditions
Interventions
pravastatin treatment (1800mg daily) 4 weeks before elective PCI
no pretreatment
Sponsors
Cardiovascular Division, Hyogo College of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Stable angina pectoris 2)Culprit lesion involving 75% or more of the stenosis 3)Patients with dyslipidemia: LDL-cho >=100mg/dL and patients who are judged by the investigator as needing cholesterol lowering therapy 4)Patients providing written consent for participation in this clinical trial on their own volition after receiving a thorough explanation of the study
Exclusion criteria
Exclusion criteria: 1)Target PCI lesion is left main coronary artery 2)Target PCI lesion is graft stenosis or in-stent restenosis 3)Patients on hemodialysis 4)Patients with acute coronary syndrome 5)Patients with contraindication of antiplatelet of anticoagulation drug 6)Patients with a history of hypersensitivity to any of the components of the product 7)Patients who are judged by the principal investigator to be ineligible for enrollment in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in index of microcirculatory index | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Absolute value of the CK-MB and high-sensitive troponin I measured at 8 and 24 hours after PCI 2)Absolute and percent changes of lipid profiles 3)Absolute and percent changes of high-sensitive CRP, VCAM-1, and MMP-9 | — |
Countries
Japan
Contacts
Public ContactKenichi Fujii
Hyogo College of Medicine Cardiovascular Division
Outcome results
None listed